Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 studyAlexandre Bazinet, Guillermo Garcia‐Manero, Elias Jabbour et al.|The Lancet Haematology|2022Cited by 85